Physician profile
Randy Taylor
NPI 1750490702
$9,084.51
in general payments reported to CMS, 2019-2025
46 companies · $2,698 in 2025
The $2,698 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $211 · 2021: $193 · 2022: $860 · 2023: $2,039 · 2024: $2,292 · 2025: $2,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,029.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,076.16 | 2023-2025 | Apretude, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $911.65 | 2020-2025 | Yeztugo, Biktarvy, Epclusa |
| Glaxosmithkline, LLC. | $667.07 | 2022-2025 | Bexsero, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $562.02 | 2022-2025 | Invega Sustenna |
| Alexion Pharmaceuticals, INC. | $485.14 | 2022-2025 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $374.32 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $364.19 | 2023-2025 | Airsupra, Lynparza, Farxiga |
| Amgen INC. | $328.91 | 2019-2025 | Evenity, Krystexxa, Otezla |
| Janssen Biotech, INC. | $257.63 | 2025 | Carvykti, Rybrevant |
| Teva Pharmaceuticals USA, INC. | $238.73 | 2020-2023 | Austedo Xr |
| Karyopharm Therapeutics INC. | $238.58 | 2022-2023 | Xpovio |
| Csl Behring | $222.56 | 2022-2025 | Hizentra |
| Lilly USA, LLC | $217.59 | 2023-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $188.38 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Jazz Pharmaceuticals INC. | $150.00 | 2024 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $149.56 | 2019-2025 | Ozempic |
| Exact Sciences Corporation | $147.69 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.48 | 2019-2024 | Jardiance |
| Incyte Corporation | $140.00 | 2025 | Monjuvi |
| Napo Pharmaceuticals INC | $127.81 | 2025 | Mytesi |
| Bayer Healthcare Pharmaceuticals INC. | $127.35 | 2022-2024 | |
| Genentech USA, INC. | $125.28 | 2019 | |
| Acadia Pharmaceuticals INC | $125.00 | 2022 | |
| Paratek Pharmaceuticals, INC. | $124.24 | 2023 | Nuzyra |
| Pfizer INC. | $123.26 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $123.06 | 2024 | |
| Neurocrine Biosciences, INC. | $122.17 | 2023 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $121.82 | 2023 | Reblozyl |
| Astellas Pharma US INC | $121.39 | 2023-2024 | Veozah |
| Alkermes, INC. | $120.00 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $119.32 | 2021 | |
| Puma Biotechnology, INC. | $117.75 | 2023 | Nerlynx |
| Melinta Therapeutics, LLC | $109.89 | 2019 | |
| Abbott Laboratories | $91.26 | 2021-2024 | Freestyle Libre 3, Eterna |
| Dexcom, INC. | $72.87 | 2021-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $67.78 | 2023-2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $56.77 | 2025 | Zoryve |
| Boston Scientific Corporation | $54.94 | 2025 | Wavewriter Alpha Prime 16 |
| Seqirus USA INC | $45.73 | 2023-2025 | Fluad Quadrivalent, Flucelvax Quadrivalent, Flucelvax |
| Abbvie INC. | $24.14 | 2021 | |
| Sanofi Pasteur INC. | $20.44 | 2024 | |
| Becton, Dickinson and Company | $17.79 | 2024 | Bd Max System, Bd Max Instrument |
| Cranial Technologies, INC | $17.67 | 2024 | Doc Band |
| Ultragenyx Pharmaceutical INC. | $15.66 | 2023 | |
| Hikma Pharmaceuticals USA | $14.31 | 2019 | |
| Cipher Pharmaceuticals US LLC | $14.15 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.